MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Kodu・Aktsiate loetelu・Inmode Ltd

Inmode Ltd

Suletud

SektorTervishoid

14.63 2.24

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.58

Max

14.69

Põhinäitajad
By Trading Economics
Sissetulek	5.2M 27M
Müük	11M 104M
P/E Sektori keskmine	9.783 63.808
Kasumimarginaal	26.022
Töötajad	660
EBITDA	5.7M 31M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+16.04% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-140M 886M
Eelmine avamishind	12.39
Eelmine sulgemishind	14.63

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

14.1 / 14.44 Toetus ja vastupanu

Inmode Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. apr 2026, 20:26 UTC

Omandamised, ülevõtmised, äriostud

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17. apr 2026, 18:15 UTC

Uudisväärsed sündmused

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17. apr 2026, 16:49 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

18. apr 2026, 01:00 UTC

Uudisväärsed sündmused

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17. apr 2026, 22:58 UTC

Tulu

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17. apr 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17. apr 2026, 20:52 UTC

Tulu

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17. apr 2026, 20:50 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

17. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. apr 2026, 20:29 UTC

Tulu

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

UCB to Buy Neurona Therapeutics for Up to $1.15B

17. apr 2026, 19:34 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

17. apr 2026, 19:34 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17. apr 2026, 19:31 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17. apr 2026, 19:26 UTC

Market Talk

U.S. Natural Gas Futures Edge Up -- Market Talk

17. apr 2026, 19:21 UTC

Market Talk

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17. apr 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17. apr 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17. apr 2026, 18:57 UTC

Uudisväärsed sündmused

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17. apr 2026, 18:53 UTC

Omandamised, ülevõtmised, äriostud

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17. apr 2026, 18:53 UTC

Omandamised, ülevõtmised, äriostud

UCB 2026 Rev Guidance Unchanged

17. apr 2026, 18:52 UTC

Omandamised, ülevõtmised, äriostud

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17. apr 2026, 18:52 UTC

Omandamised, ülevõtmised, äriostud

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17. apr 2026, 18:14 UTC

Market Talk

Uudisväärsed sündmused

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17. apr 2026, 18:00 UTC

Uudisväärsed sündmused

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17. apr 2026, 18:00 UTC

Uudisväärsed sündmused

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17. apr 2026, 17:31 UTC

Market Talk

Uudisväärsed sündmused

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17. apr 2026, 17:26 UTC

Market Talk

Tulu

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Inmode Ltd Prognoos

Hinnasiht

By TipRanks

16.04% tõus

12 kuu keskmine prognoos

Keskmine 17 USD 16.04%

Kõrge 21 USD

Madal 15 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Inmode Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Inmode Ltd aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

14.1 / 14.44Toetus ja vastupanu

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Inmode Ltd

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.